J Clin Oncol 2003, 21:2689–2696.PubMed 97. Ferone D, Saveanu A, Culler MD, Arvigo M, Rebora A, Gatto F, Minuto F, Jaquet P: Novel chimeric somatostatin analogs: facts and perspectives. Eur J Endocrinol 2007, 156:23–28. Idasanutlin 98. Ferone D, Arvigo M, Semino C, Jaquet P, Saveanu A, Taylor JE, Moreau JP, Culler MD, Albertelli M, Minuto F, Barreca

A: Somatostatin and dopamine receptor expression in lung carcinoma cells and selleck effects of chimeric somatostatin-dopamine molecules on cell proliferation. Am J Physiol Endocrinol Metab 2005, 289:E1044–50.PubMed 99. Kidd M, Modlin IM, Black JW, Boyce M, Culler M: A comparison of the effects of gastrin, somatostatin and dopamine receptor ligands on rat gastric enterochromaffin-like cell secretion and proliferation. Regul Pept 2007, 143:109–117.PubMed 100. Sharif N, Gendron L, Wowchuk J, Sarret P, Mazella J, Beaudet A, Stroh T: Coexpression of somatostatin receptor subtype 5 affects internalization and trafficking of somatostatin receptor subtype 2. Endocrinology 2007, 148:2095–2105.PubMed 101. Baragli A, Alturaihi H, Watt HL, Abdallah A, Kumar U: Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2. Co-immunoprecipitation and fluorescence

resonance energy transfer analysis. Cell Signal 2007, 19:2304–2316.PubMed 102. Kaltsas G, Rockall A, Papadogias Nirogacestat D, Reznek R, Grossman AB: Recent advances in radiological and radionuclide imaging and therapy of neuroendocrine

tumours. European Journal of Endocrinology 2004, 151:15–27.PubMed 103. Sun LC, Luo J, Mackey VL, Fuselier JA, Coy DH: Effects of camptothecin on tumor cell proliferation and angiogenesis when coupled to a bombesin analog used as a targeted delivery vector. Anticancer Drugs 2007, 18:341–348.PubMed 104. Fjälling M, Andersson P, Forssell-Aronsson E, Grétarsdóttir J, Johansson V, Tisell LE, Wängberg B, Nilsson O, Berg G, Michanek A, Lindstedt G, Ahlman Etofibrate H: Systemic radionuclide therapy using indium-111-DTPA-D-Phe1-octreotide in midgut carcinoid syndrome. J Nucl Med 1996, 37:1519–1521.PubMed 105. Heppeler A, Froidevaux S, Eberle AN, Maecke HR: Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem 2000, 7:971–994.PubMed 106. Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J: The clinical value of (90Y-DOTA)-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001, 12:941–945.PubMed 107. Forrer F, Valkema R, Kwekkeboom DJ, de Jong M, Krenning EP: Neuroendocrine Tumors. Peptide receptor radionuclide therapy. Best Pract Res Clin Endocrinol Metab 2007, 21:111–29.